Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CA4 | P22748 | 3/20 | 0.48 |
| ▸ | CA5A | P35218 | 3/20 | 0.48 |
| ▸ | CA7 | P43166 | 3/20 | 0.48 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.48 |
| ▸ | NT5E | P21589 | 1/20 | 0.47 |
| ▸ | TACR2 | P21452 | 3/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 8/20 | 0.44 |
| ▸ | CDC25B | P30305 | 6/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.43 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10261481 | 1.00 | CA12 (0.48) | CA12CA1CA2CA4CA5A | |
| SCHEMBL26273709 | 0.93 | CA12 (0.48) | CA12CA1CA2CA4CA5A | |
| SCHEMBL3248351 | 0.92 | NT5E (0.47) | CA12CA1CA2CA4CA5A | |
| SCHEMBL10261679 | 0.91 | PTPN1 (0.47) | CA12CA1CA2CA4CA5A | |
| SCHEMBL24086079 | 0.89 | CA12 (0.60) | CA12CA1CA2CA4CA5A | |
| SCHEMBL21851786 | 0.89 | CA12 (0.60) | CA12CA1CA2CA4CA5A | |
| SCHEMBL4874686 | 0.89 | CA12 (0.60) | CA12CA1CA2CA4CA5A | |
| SCHEMBL13857172 | 0.89 | PTPN1 (0.46) | NT5ETACR2PTPN1CDC25BPTPN2 | |
| SCHEMBL3248483 | 0.88 | NT5E (0.56) | NT5ETACR2PTPN1CDC25BPTPN2 | |
| SCHEMBL24107840 | 0.88 | NT5E (0.56) | NT5ETACR2PTPN1CDC25BPTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218342-A1 | SITE-SPECIFIC GLYCAN REMODELING OF LYSOSOMAL ENZYMES AND APPLICATIONS THEREOF | UNIVERSITY OF MARYLAND, COLLEGE PARK | 2024-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218342-A1 | SITE-SPECIFIC GLYCAN REMODELING OF LYSOSOMAL ENZYMES AND APPLICATIONS THEREOF | GAA, MAN2B1, M6PR | CA12 906/4885CA1 2735/4885CA2 2064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.